| Literature DB >> 31806658 |
Molly Fisher1, Ladan Golestaneh1, Michael Allon2, Kenneth Abreo3, Michele H Mokrzycki4.
Abstract
Bloodstream infections are an important cause of hospitalizations, morbidity, and mortality in patients receiving hemodialysis. Eliminating bloodstream infections in the hemodialysis setting has been the focus of the Centers for Disease Control and Prevention (CDC) Making Dialysis Safer for Patients Coalition and, more recently, the CDC's partnership with the American Society of Nephrology's Nephrologists Transforming Dialysis Safety Initiative. The majority of vascular access-associated bloodstream infections occur in patients dialyzing with central vein catheters. The CDC's core interventions for bloodstream infection prevention are the gold standard for catheter care in the hemodialysis setting and have been proven to be effective in reducing catheter-associated bloodstream infection. However, in the United States hemodialysis catheter-associated bloodstream infections continue to occur at unacceptable rates, possibly because of lapses in adherence to strict aseptic technique, or additional factors not addressed by the CDC's core interventions. There is a clear need for novel prophylactic therapies. This review highlights the recent advances and includes a discussion about the potential limitations and adverse effects associated with each option.Entities:
Keywords: Centers for Disease Control and Prevention (U.S.); United States; bacteremia; catheter-related infections; central venous catheter; central venous catheters; hemodialysis; hemodialysis access; hospitalization; humans; morbidity; mortality; nephrologists; nephrology; renal dialysis; sepsis; vascular access
Mesh:
Substances:
Year: 2019 PMID: 31806658 PMCID: PMC6946076 DOI: 10.2215/CJN.06820619
Source DB: PubMed Journal: Clin J Am Soc Nephrol ISSN: 1555-9041 Impact factor: 8.237